Peer Review | Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy | September 24, 2025 Share
Peer Review | ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials | April 23, 2025 Share
White Paper | 2024 Annual Meeting | Framework for Integrating Change in ctDNA Levels in Advanced Cancer Clinical Trials to Support Meta-analyses for Intermediate Endpoint Validation | November 9, 2024 Share
Poster | SITC 2024 | The Impact of Treatment Modalities on Use of ctDNA as an Early Endpoint in aNSCLC Trials | November 9, 2024 Share
Public Comment | Use of Circulating Tumor DNA for Early Stage Solid Tumor Drug Development | August 2, 2024 Share
Peer Review | Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages | May 7, 2024 Share
